Teva and Immunai partner to improve clinical decision making

The companies will focus on mechanisms of action, dose selection and biomarker analyses

Teva Pharmaceuticals and artificial intelligence (AI)-driven Immunai have entered into a partnership aimed at optimising clinical trials in immunology and immuno-oncology.

The multi-year collaboration will utilise Immunai’s proprietary immune cell atlas, AMICA, as well as its AI model, the Immunodynamics Engine (IDE), to improve clinical decision making in Teva’s immunology trials.

Though financial details of the deal have not been disclosed, Immunai, which specialises in mapping the human immune system, outlined that the companies will focus on areas including drug mechanism of action, dose selection and biomarker analyses.

The partners could also expand the collaboration to cover broader aspects of Teva’s research and development portfolio.

Eran Harary, Senior Vice President of Global Early Clinical Development at Teva, said: “This collaboration will provide important insights into patient responses and treatment mechanisms in immunology and immuno-oncology, allowing us to optimise our clinical trials and improve outcomes for patients.”

Also commenting on the alliance, Immunai’s Chief Executive Officer, Noam Solomon, said: “Bringing a drug to market is inherently challenging, time-consuming and costly. Through our partnership with Teva, we are eager to utilise our AI-based engine, the IDE, to streamline this process and facilitate the delivery of new therapies to patients.”

The announcement comes less than two months after Immunai unveiled a multi-year collaboration with AstraZeneca for advanced clinical trial optimisation.

The agreement also focuses on clinical decision making, including dose selection, mechanisms of action, patient responder versus non-responder analysis, as well as biomarker identification.